GREY:ATBPF - Post by User
Comment by
Actuarialon Feb 11, 2021 1:45pm
106 Views
Post# 32542440
RE:RE:RE:RE:IR responce
RE:RE:RE:RE:IR responceLayth1990, I don't think Nuance will wait for phase 3 results in US as it will take much longer than if they do it themselves in China. While Nuance wait for ATE phase 3 results in US could have save some money, Nuance would also loss sales as any patent has an expiry date. Nuance has a lot of cash to burn and taking phase 3 in China is extremely cheap. In Canada, we pay people who participate clinical trials; in China, people pay (particularly for cancer drug developments) or free of charge (most likely in ATB-346 case) to participate clinical trials. Nuance only need to pay ATE for drug production cost + some PR cost to hospitals and doctors + some data analytics expense.
Layth1990 wrote: i think, first they paid 100m to obtain the license in china. the double digit royalties from revenues will benefit antibe later on. This will give you an idea on how strong is the proof of concept. i think nuance will wait for phase 3 results in us. it will file it in china after, this way it will reduce the costs of clinical trials. nuance will be responsible for manifacturing and marketing our drug in china , in return we will get royalties.